Hostname: page-component-7c8c6479df-nwzlb Total loading time: 0 Render date: 2024-03-29T08:02:52.564Z Has data issue: false hasContentIssue false

Amisulpride-induced mania in a patient with schizophrenia

Published online by Cambridge University Press:  02 January 2018

B. P. Murphy*
Affiliation:
Early Psychosis Prevention and Intervention Centre, ORYGEN Youth Health, Locked Bay 10 (35 Poplar Road), Parkville, Victoria, Australia 3052
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © 2003 The Royal College of Psychiatrists 

Numerous case reports of atypical antipsychotics inducing hypomanic/manic symptoms have been published; most concern the use of risperidone and olanzapine (Reference Aubry, Simon and BertschyAubry et al, 2000), but quetiapine (Reference BenazziBenazzi, 2001) and ziprasidone (Reference Lu, Lundgren and EscalonaLu et al, 2002) have also been implicated. A literature search using Medline and PubMed revealed no such reports associated with amisulpride. Although the manufacturer has accumulated a small number of reports of manic symptoms developing during amisulpride treatment, a recent internal review concluded that no causality could be established (Sanofi-Synthelabo, personal communication, 2002). I report a case of amisulpride-induced mania.

A 17-year-old female with a 4-year history of schizophrenia was commenced on amisulpride for persistent negative symptoms. It was cross-titrated with olanzapine, over a 4-week period, to 400 mg. She continued taking citalopram 20 mg, which had been started 6 months previously on the basis that her negative symptoms could be secondary to a masked depression. On commencement of amisulpride her negative symptoms, as rated on the Scale for the Assessment of Negative Symptoms (SANS; Reference AndreasenAndreasen, 1982), rapidly and linearly improved. Her mood, however, continued to rise and by 3 months she had developed a manic episode without psychotic features. She exhibited insomnia, hyperactivity, distractibility, disinhibition and an abnormally and persistently elevated mood that continued despite the immediate cessation of citalopram. There was no evidence of substance misuse or akathisia. These features improved after halving the amisulpride to 200 mg and re-introducing olanzapine 15 mg. They fully remitted within days of stopping the amisulpride. No other concomitant medication was used. The delay in development of overt manic symptoms may reflect having to overcome a baseline SANS score of 68.

The mechanism of action of mood changes induced by atypical antipsychotics is unknown, with speculation centring exclusively on a 5-HT2a:D2 economy. Lane et al (Reference Lane, Lin and Chang1998) argue that a higher ratio will increase frontal dopamine release, whereas others point to the combined blockade enhancing the ability of 5-HT1a to release frontal dopamine (Reference Ichikawa, Ishii and BonaccorsoIchikawa et al, 2001). These theories do not explain the manicogenic effects of amisulpride, which has no serotonin affinity. I propose that the ability of low doses of amisulpride to differentially block presynaptic D2 and D3 autoreceptors enhances dopamine transmission in the frontal cortex and can lead to the development of manic symptoms in susceptible subjects. Presumably this mechanism contributes to its antidepressant efficacy, for which it is used in many countries. The theory implies induction of manic features at low doses only.

Footnotes

EDITED BY STANLEY ZAMMIT

Declaration of interest

B.P.M. works for ORYGEN, which has received an unrestricted educational grant from Sanofi-Synthelabo.

References

Andreasen, N. C. (1982) The Scale for the Assessment of Negative Symptoms. Iowa, IA: University of Iowa.Google Scholar
Aubry, J.-M., Simon, A. E. & Bertschy, G. (2000) Possible induction of mania and hypomania by olanzapine and risperidone: a critical review of reported cases. Journal of Clinical Psychiatry, 61, 649651.Google Scholar
Benazzi, F. (2001) Quetiapine-associated hypomania in a woman with schizoaffective disorder. Canadian Journal of Psychiatry, 46, 182183.Google Scholar
Ichikawa, J., Ishii, H., Bonaccorso, S., et al (2001) 5-HT2a and D2 receptor blockade increases cortical DA release via 5-HT1a receptor activation: a possible mechanism of action of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry, 76, 15211531.Google Scholar
Lane, H.Y., Lin, Y. C. & Chang, W. H. (1998) Mania induced by risperidone: dose related? Journal of Clinical Psychiatry, 59, 8586.CrossRefGoogle ScholarPubMed
Lu, B.Y., Lundgren, R., Escalona, P. R., et al (2002) A case of ziprasidone-induced mania and the role of 5-HT2a in mood changes induced by atypical antipsychotics. Journal of Clinical Psychiatry, 63, 11851186.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.